Executive Interviews

Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia.

Wizard Power develops world leading Concentrating Solar Power (CSP) technology and licenses it to developers of large-scale energy projects. Its core product is the Big Dish, a multi-purpose, ultra high temperature solar energy delivery platform that provides the world’s most competitive on-demand utility scale solar energy. Aside from electricity generation, it also provides energy for […]

Optiscan is a global leader in the development and application of miniaturised microscopic imaging technologies for medical markets. Optiscan’s imaging technology allows live cellular imaging for earlier and better detection of pre-cancerous and cancerous lesions and more accurate resection during surgery. Optiscan’s technology has been incorporated into Pentax endoscopes since 2006 and will soon be […]

Over the past four years, Syngas Limited (ASX:SYS) has invested in and established a biomass/clean energy business (BioSyngas Pty Ltd) on the basis that commercial opportunities would be created through the introduction of carbon management initiatives in Australia. Syngas has now reached the stage where a separate entity, BioSyngas Pty Ltd, is ready to launch, […]

Capita Asset Management Limited is a Brisbane based funds management company specialising in property syndicates and mortgage lending. The company’s latest investment offer is the ‘Capita Adelaide Street Trust’ which is being formed to acquire and develop an approved 8 Lot residential subdivision in Clayfield, Brisbane.

Life Science sector represents the essential industry for Wholesale Investor. A great number of small, medium and start-up life science enterprises are directly promoted to active investors and deal makers.

AIMEDICS has developed the HypoMon which is the world’s first non-invasive night time low blood glucose management system. More than 11 million diabetic insulin users in the developed world suffer from bouts of dangerously low blood glucose several nights per month. Independent USA market research indicates that the HypoMon is a unique product addressing a […]

GPL’S business focus is on delivering generation solutions using GPL’s proven and patented GRANEX® technology, which generates electricity from low-to-medium temperature heat sources, such as industrial recovered waste heat from sources such as generator sets, smelters and other common industrial processes.

The Benlee Property Trust No 5 is the 5th trust established by the property manager in the last 3 years. The trust has purchased two Brisbane properties for $7m & $5.5m which were settled on 28 June 2012 by the stage one equity raising of $7.4m and the balance by bank debt.